
Jounce Therapeutics JNCE
Annual report 2022
added 04-28-2023
Jounce Therapeutics Shares 2011-2026 | JNCE
Annual Shares Jounce Therapeutics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 51.7 M | 49.9 M | 34.2 M | 33.1 M | 32.6 M | 30.1 M | 30.2 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 51.7 M | 30.1 M | 37.4 M |
Quarterly Shares Jounce Therapeutics
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 51.7 M | - | 51.6 M | 51.3 M | 51.2 M | 51.2 M | 46 M | 41.7 M | 34.2 M | 34.1 M | 34 M | 33.7 M | 33.1 M | 33 M | 33 M | 32.9 M | 32.6 M | 32.5 M | 32.4 M | 32.2 M | 32.2 M | 32.1 M | 23.5 M | 2.42 M | 2.13 M | 1.99 M | 1.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 51.7 M | 1.9 M | 32.3 M |
Shares of other stocks in the Biotechnology industry
| Issuer | Shares | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
33.4 M | - | 2.43 % | $ 254 M | ||
|
AbCellera Biologics
ABCL
|
299 M | $ 3.55 | -0.42 % | $ 1.06 B | ||
|
Acorda Therapeutics
ACOR
|
1.24 M | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
12.1 M | - | 4.01 % | $ 150 M | ||
|
Advaxis
ADXS
|
6.02 M | - | -9.65 % | $ 45.9 M | ||
|
AC Immune SA
ACIU
|
75 M | $ 3.24 | 3.35 % | $ 229 M | ||
|
I-Mab
IMAB
|
187 M | - | - | $ 866 M | ||
|
Aeglea BioTherapeutics
AGLE
|
78.2 M | - | - | $ 1.01 B | ||
|
AgeX Therapeutics
AGE
|
1.08 K | - | -10.17 % | $ 12.2 K | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
219 M | - | - | $ 40.3 B | ||
|
Biophytis SA
BPTS
|
118 M | - | -13.47 % | $ 169 M | ||
|
Albireo Pharma
ALBO
|
19.2 M | - | -0.23 % | $ 916 M | ||
|
Aileron Therapeutics
ALRN
|
17.9 M | - | 10.36 % | $ 9.8 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.58 M | - | -1.52 % | $ 24.7 M | ||
|
ADC Therapeutics SA
ADCT
|
76.7 M | $ 4.14 | -1.9 % | $ 105 M | ||
|
Midatech Pharma plc
MTP
|
80.5 M | - | -18.52 % | $ 27.3 M | ||
|
Aptorum Group Limited
APM
|
5.45 M | $ 0.82 | 4.22 % | $ 4.47 M | ||
|
argenx SE
ARGX
|
51.1 M | $ 714.55 | 1.6 % | $ 25 B | ||
|
Adverum Biotechnologies
ADVM
|
19.8 M | - | - | $ 86.2 M | ||
|
Ascendis Pharma A/S
ASND
|
54.8 M | $ 231.26 | 0.1 % | $ 5 B | ||
|
Alterity Therapeutics Limited
ATHE
|
2.41 B | $ 3.4 | -5.82 % | $ 8.18 B | ||
|
Atea Pharmaceuticals
AVIR
|
81.5 M | $ 6.09 | 0.66 % | $ 496 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
45 M | - | - | $ 26.5 M | ||
|
Applied Molecular Transport
AMTI
|
38.8 M | - | - | $ 10.1 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
27.4 M | $ 6.6 | -0.45 % | $ 181 M | ||
|
Институт стволовых клеток человека
ISKJ
|
75 M | - | - | - | ||
|
BioCardia
BCDA
|
21.2 M | $ 1.37 | 7.87 % | $ 29 M | ||
|
Akero Therapeutics
AKRO
|
67.1 M | - | - | $ 3.67 B | ||
|
Athersys
ATHX
|
224 M | - | 3.77 % | $ 22.4 M | ||
|
Akouos
AKUS
|
34.4 M | - | 0.23 % | $ 488 M | ||
|
Acer Therapeutics
ACER
|
15.8 M | - | 2.71 % | $ 14 M | ||
|
ARCA biopharma
ABIO
|
16.8 M | - | 1052.0 % | $ 415 M | ||
|
Allena Pharmaceuticals
ALNA
|
68 M | - | 3.16 % | $ 1.9 M | ||
|
Aeterna Zentaris
AEZS
|
115 M | - | 5.93 % | $ 314 M | ||
|
AlloVir
ALVR
|
5.01 M | - | 4.14 % | $ 49.1 M | ||
|
Catalyst Biosciences
CBIO
|
89.3 M | $ 11.29 | -2.5 % | $ 1.01 B | ||
|
Anika Therapeutics
ANIK
|
14.7 M | $ 14.61 | 1.71 % | $ 214 M | ||
|
Aptinyx
APTX
|
67.7 M | - | -39.0 % | $ 4.57 M | ||
|
Aptose Biosciences
APTO
|
699 K | - | -45.71 % | $ 1.2 M | ||
|
AVEO Pharmaceuticals
AVEO
|
32.7 M | - | - | $ 521 M | ||
|
Ayala Pharmaceuticals
AYLA
|
15.4 M | - | - | $ 7.46 M | ||
|
BioNTech SE
BNTX
|
244 M | $ 92.9 | 2.61 % | $ 27.2 B | ||
|
Aytu BioScience
AYTU
|
6.28 M | $ 2.64 | - | $ 16.6 M | ||
|
CNS Pharmaceuticals
CNSP
|
382 K | $ 2.36 | -3.67 % | $ 902 K | ||
|
CorMedix
CRMD
|
72 K | $ 6.57 | 0.46 % | $ 473 K | ||
|
Avenue Therapeutics
ATXI
|
1.3 M | - | -52.27 % | $ 4.45 M | ||
|
Burford Capital Limited
BUR
|
219 M | $ 8.24 | 2.36 % | $ 1.33 B | ||
|
Autolus Therapeutics plc
AUTL
|
255 M | $ 1.5 | -0.99 % | $ 383 M | ||
|
Athira Pharma
ATHA
|
38.5 M | - | - | $ 269 M | ||
|
CureVac N.V.
CVAC
|
186 M | - | - | $ 867 M |